Cargando…

Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors

Aza-peptide aldehydes and ketones are a new class of reversible protease inhibitors that are specific for the proteasome and clan CD cysteine proteases. We designed and synthesised aza-Leu derivatives that were specific for the chymotrypsin-like active site of the proteasome, aza-Asp derivatives tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Corrigan, Thomas S., Lotti Diaz, Leilani M., Border, Sarah E., Ratigan, Steven C., Kasper, Kayla Q., Sojka, Daniel, Fajtova, Pavla, Caffrey, Conor R., Salvesen, Guy S., McElroy, Craig A., Hadad, Christopher M., Doğan Ekici, Özlem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470110/
https://www.ncbi.nlm.nih.gov/pubmed/32633155
http://dx.doi.org/10.1080/14756366.2020.1781107
_version_ 1783578520825364480
author Corrigan, Thomas S.
Lotti Diaz, Leilani M.
Border, Sarah E.
Ratigan, Steven C.
Kasper, Kayla Q.
Sojka, Daniel
Fajtova, Pavla
Caffrey, Conor R.
Salvesen, Guy S.
McElroy, Craig A.
Hadad, Christopher M.
Doğan Ekici, Özlem
author_facet Corrigan, Thomas S.
Lotti Diaz, Leilani M.
Border, Sarah E.
Ratigan, Steven C.
Kasper, Kayla Q.
Sojka, Daniel
Fajtova, Pavla
Caffrey, Conor R.
Salvesen, Guy S.
McElroy, Craig A.
Hadad, Christopher M.
Doğan Ekici, Özlem
author_sort Corrigan, Thomas S.
collection PubMed
description Aza-peptide aldehydes and ketones are a new class of reversible protease inhibitors that are specific for the proteasome and clan CD cysteine proteases. We designed and synthesised aza-Leu derivatives that were specific for the chymotrypsin-like active site of the proteasome, aza-Asp derivatives that were effective inhibitors of caspases-3 and -6, and aza-Asn derivatives that inhibited S. mansoni and I. ricinus legumains. The crystal structure of caspase-3 in complex with our caspase-specific aza-peptide methyl ketone inhibitor with an aza-Asp residue at P1 revealed a covalent linkage between the inhibitor carbonyl carbon and the active site cysteinyl sulphur. Aza-peptide aldehydes and ketones showed no cross-reactivity towards cathepsin B or chymotrypsin. The initial in vitro selectivity of these inhibitors makes them suitable candidates for further development into therapeutic agents to potentially treat multiple myeloma, neurodegenerative diseases, and parasitic infections.
format Online
Article
Text
id pubmed-7470110
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-74701102020-09-15 Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors Corrigan, Thomas S. Lotti Diaz, Leilani M. Border, Sarah E. Ratigan, Steven C. Kasper, Kayla Q. Sojka, Daniel Fajtova, Pavla Caffrey, Conor R. Salvesen, Guy S. McElroy, Craig A. Hadad, Christopher M. Doğan Ekici, Özlem J Enzyme Inhib Med Chem Short Communication Aza-peptide aldehydes and ketones are a new class of reversible protease inhibitors that are specific for the proteasome and clan CD cysteine proteases. We designed and synthesised aza-Leu derivatives that were specific for the chymotrypsin-like active site of the proteasome, aza-Asp derivatives that were effective inhibitors of caspases-3 and -6, and aza-Asn derivatives that inhibited S. mansoni and I. ricinus legumains. The crystal structure of caspase-3 in complex with our caspase-specific aza-peptide methyl ketone inhibitor with an aza-Asp residue at P1 revealed a covalent linkage between the inhibitor carbonyl carbon and the active site cysteinyl sulphur. Aza-peptide aldehydes and ketones showed no cross-reactivity towards cathepsin B or chymotrypsin. The initial in vitro selectivity of these inhibitors makes them suitable candidates for further development into therapeutic agents to potentially treat multiple myeloma, neurodegenerative diseases, and parasitic infections. Taylor & Francis 2020-07-07 /pmc/articles/PMC7470110/ /pubmed/32633155 http://dx.doi.org/10.1080/14756366.2020.1781107 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Corrigan, Thomas S.
Lotti Diaz, Leilani M.
Border, Sarah E.
Ratigan, Steven C.
Kasper, Kayla Q.
Sojka, Daniel
Fajtova, Pavla
Caffrey, Conor R.
Salvesen, Guy S.
McElroy, Craig A.
Hadad, Christopher M.
Doğan Ekici, Özlem
Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors
title Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors
title_full Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors
title_fullStr Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors
title_full_unstemmed Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors
title_short Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors
title_sort design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470110/
https://www.ncbi.nlm.nih.gov/pubmed/32633155
http://dx.doi.org/10.1080/14756366.2020.1781107
work_keys_str_mv AT corriganthomass designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors
AT lottidiazleilanim designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors
AT bordersarahe designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors
AT ratiganstevenc designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors
AT kasperkaylaq designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors
AT sojkadaniel designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors
AT fajtovapavla designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors
AT caffreyconorr designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors
AT salvesenguys designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors
AT mcelroycraiga designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors
AT hadadchristopherm designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors
AT doganekiciozlem designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors